Tests & services
Select disease state
Select modality
IDHNow for AML Sponsored Testing Program
NeoGenomics has partnered with Servier to offer eligible acute myeloid leukemia (AML) patients a rapid IDH1/2 test by polymerase chain reaction (PCR) with a 3- to 5-day turnaround time to help guide your treatment decisions.
Patient eligibility criteria:
- Patient has newly diagnosed AML, not previously treated
- Patient does not have a known IDH1 mutation from a previous test
- Patient lives and receives treatment in the United States or a US territory
- Patient has not previously been tested under this program
My COMPASS® test results provided definitive answers both on my diagnosis and my prognosis so that I could spend more time with my family.